Pituitary gigantism due to a novel AIP germline splice-site variant
in Endocrine OncologySearch for other papers by Elisa Lamback in
Current site
Google Scholar
PubMed
Search for other papers by Renan Lyra Miranda in
Current site
Google Scholar
PubMed
Search for other papers by Leila Chimelli in
Current site
Google Scholar
PubMed
Search for other papers by Felipe Andreiuolo in
Current site
Google Scholar
PubMed
Search for other papers by Leandro Kasuki in
Current site
Google Scholar
PubMed
Search for other papers by Luiz Eduardo Armondi Wildemberg in
Current site
Google Scholar
PubMed
Search for other papers by Monica R Gadelha in
Current site
Google Scholar
PubMed
Pituitary gigantism is a rare pediatric disorder caused by excess growth hormone (GH) secretion. In almost 50% of cases, a genetic cause can be identified, with pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene being the most common. We present a case of a 11-year-old boy who exhibited progressive vision loss, associated with accelerated linear growth and weight gain. On physical examination, he had enlarged hands, right eye amaurosis, and was already above his target height. Increased GH and IGF-I concentrations confirmed the diagnosis of pituitary gigantism. A magnetic resonance imaging showed a giant sellar lesion with supra- and para-sellar extensions. He underwent two surgeries which did not achieve cure or visual improvement. Histopathological analysis revealed a sparsely granulated tumor, negative for somatostatin receptor type 2 (SST2) and immunoreactivity score of 6 for somatostatin receptor type 5 (SST5). Our published artificial intelligence prediction model predicted an 83% chance of not responding to first-generation somatostatin receptor ligands. Pasireotide was therefore prescribed and afterwards cabergoline was added on. IGF-I concentrations decreased, but did not normalize. We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of AIP gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines.
Endocrine Oncology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
As an open-access journal, Endocrine Oncology articles are immediately available to read on publication, without restriction. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Feb 2021 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 141 | 141 | 51 |
| PDF Downloads | 132 | 132 | 36 |
Online ISSN: 2634-4793
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519